REFERENCES
- Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of
coronavirus disease 2019: a model-based analysis. Lancet Infect
Dis. 2020;20:669-77.
- Infectious Diseases Society of America Guidelines on the Treatment and
Management of Patients with COVID-19. Available at:
https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/.
Accessed in November, 2020.
- Falavigna M, Colpani V, Stein C, et al. Guidelines for the
pharmacological treatment of COVID-19. The task-force/consensus
guideline of the Brazilian Association of Intensive Care Medicine, the
Brazilian Society of Infectious Diseases and the Brazilian Society of
Pulmonology and Tisiology. Diretrizes para o tratamento farmacológico
da COVID-19. Consenso da Associação de Medicina Intensiva Brasileira,
da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de
Pneumologia e Tisiologia. Rev Bras Ter Intensiva.2020;32(2):166-196.
- Polanczyk CA, Rohsig V, Bastos GN, et al. Getting Ready for the
Covid-19 Pandemic: Experience of a Brazilian Hospital. N Engl J
Med . 2020.
- Wise J, Coombes R. Covid-19: The inside story of the RECOVERY trial.BMJ . 2020;370:m2670.
- Barda N, Riesel D, Akriv A, et al. Developing a COVID-19 mortality
risk prediction model when individual-level data are not available.Nat Commun . 2020;11:4439.
- Zhao Z, Anne C, Wei H, et al. Prediction model and risk scores of ICU
admission and mortality in COVID-19. PloS one . 2020;15,7:
e0236618.
- WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed
Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.N Engl J Med. 2020;NEJMoa2023184.
- Simonovich VA, Burgos Pratx LD, Scibona P, et al. PlasmAr Study Group.
A Randomized Trial of Convalescent Plasma in Covid-19 Severe
Pneumonia. N Engl J Med. 2020:NEJMoa2031304.
- Fang X, Mei Q, Yang T, et al. Low-dose corticosteroid therapy does not
delay viral clearance in patients with COVID-19. J Infect .
2020;81(1):147-178.
- Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for
2019-nCoV pneumonia. Lancet. 2020;395(10225):683-684.
- World Health Organization. Corticosteroids for COVID-19 guideline.
Available
at:https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1.
Accessed in December, 2020.
- De Backer D, Azoulay E, Vincent JL. Corticosteroids in severe
COVID-19: a critical view of the evidence. Crit Care.2020;24:627.
- Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, Bleeding,
Mortality, and Pathology in Hospitalized Patients With COVID-19. J Am
Coll Cardiol. 2020;76(16):1815-1826.
- Tanriverdİ E, ÇÖrtÜk M, Yildirim BZ, et al. The use of
hydroxychloroquine plus azithromycin and early hospital admission are
beneficial in Covid-19 patients: Turkey experience with real-life
data. Turk J Med Sci. 2020.
- Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with
hydroxychloroquine, azithromycin, and combination in patients
hospitalized with COVID-19. Int J Infect Di s. 2020;97:396-403.
- Cavalcanti AB, Zampieri FG, Rosa RG, et al. Coalition Covid-19 Brazil
I Investigators. Hydroxychloroquine with or without Azithromycin in
Mild-to-Moderate Covid-19. N Engl J Med.2020;383(21):2041-2052.
- Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on
Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A
Randomized Clinical Trial. JAMA. 2020;e2022240.
- Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With
Hydroxychloroquine or Azithromycin With In-Hospital Mortality in
Patients With COVID-19 in New York State. JAMA.
2020;323(24):2493–2502. doi:10.1001/jama.2020.8630
- Magagnoli J, Narendran S, Pereira F, et al. Outcomes of
hydroxychloroquine usage in United States veterans hospitalized with
Covid-19. Preprint. medRxiv. 2020;2020.04.16.20065920.
- Kalligeros M, Shehadeh F, Atalla E, et al. Hydroxychloroquine use in
hospitalised patients with COVID-19: An observational matched cohort
study. J Glob Antimicrob Resist . 2020;22:842-844.
- Lin SM, Liu KX, Lin ZH, Lin PH. Does high-flow nasal cannula oxygen
improve outcome in acute hypoxemic respiratory failure? A systematic
review and meta-analysis. Respir Med . 2017;131:58-64.
- Geng S, Mei Q, Zhu C, et al. High flow nasal cannula is a good
treatment option for COVID-19. Heart Lung . 2020;49(5):444-445.
- Yamada T, Wakabayashi M, Yamaji T, et al. Value of leukocytosis and
elevated C-reactive protein in predicting severe coronavirus 2019
(COVID-19): A systematic review and meta-analysis. Clinica
Chimica Acta; International Journal of Clinical Chemistry.2020;509:235-243.
- Huang HD, Jneid H, Aziz M, et al. Safety and Effectiveness of
Hydroxychloroquine and Azithromycin Combination Therapy for Treatment
of Hospitalized Patients with COVID-19: A Propensity-Matched Study.Cardiol Ther . 2020;9(2):523-534.
- Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation
Associated With Use of Hydroxychloroquine With or Without Concomitant
Azithromycin Among Hospitalized Patients Testing Positive for
Coronavirus Disease 2019 (COVID-19). JAMA Cardiol .
2020;1;5(9):1036-1041.
- Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and
torsade de pointes in patients with COVID-19 treated with
hydroxychloroquine/azithromycin. Heart Rhythm .
2020;17(9):1425-1433.
- Saleh M, Gabriels J, Chang D, et al. Effect of Chloroquine,
Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in
Patients With SARS-CoV-2 Infection. Circ Arrhythm
Electrophysiol . 2020;13(6):e008662.